Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000895852 | SCV001039918 | likely benign | not provided | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000895852 | SCV001142925 | uncertain significance | not provided | 2018-10-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000895852 | SCV001813565 | likely benign | not provided | 2021-03-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002539439 | SCV003590275 | uncertain significance | Inborn genetic diseases | 2021-09-16 | criteria provided, single submitter | clinical testing | The c.15113T>C (p.I5038T) alteration is located in exon 74 (coding exon 74) of the ADGRV1 gene. This alteration results from a T to C substitution at nucleotide position 15113, causing the isoleucine (I) at amino acid position 5038 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004551684 | SCV004756894 | likely benign | ADGRV1-related disorder | 2023-08-14 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |